While more research is needed to uncover how central GPR120 contributes to the neurobehavioral effects of modulating dietary n-3 PUFA, GPR120-based pharmacotherapies may offer a new management strategy for metabolic disease and psychiatric and neurological co-morbidities that encompass microglial activations. This evidence concerns the gene FFAR4 and metabolic disease.